Какова цена за Novo Nordisk A/S (NOVO-B)

Цена за Novo Nordisk A/S (NOVO-B) Это $43.92

Какова рыночная капитализация для Novo Nordisk A/S (NOVO-B)

Рыночная капитализация для Novo Nordisk A/S (NOVO-B) Это $195.10B

Novo Nordisk A/S (NOVO-B) EPS

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Год	EPS	Изменить
Недостаточно данных для указанных дат.

Год

EPS

Изменить

Недостаточно данных для указанных дат.

Компания	EPS	Разница в EPS	Страна
Eli Lilly and Company LLY.US	$29.85	724.79%	US
Johnson & Johnson JNJ.US	$8.65	139.01%	US
AbbVie Inc. ABBV.US	$3.55	-1.91%	US
Roche Holding AG RO.SW	$20.39	463.37%	CH
Merck & Co., Inc. MRK.US	$1.26	-65.18%	US

Компания

EPS

Разница в EPS

Страна